Cargando…
Six‐month outcomes in postapproval HeartMate3 patients: A single‐center US experience
BACKGROUND: The European CE Mark approval study and the MOMENTUM 3 trial demonstrated safety and a reduction in hemocompatibility‐related adverse events with the use of HeartMate 3 (HM3) device. This single‐center study investigated the real‐world experience in HM3 patients since FDA approval. METHO...
Autores principales: | Bansal, Aditya, Akhtar, Faisal, Desai, Sapna, Velasco‐Gonzalez, Cruz, Bansal, Anirudh, Teagle, Angie, Shridhar, Avni, Webre, Karen, Ostrow, Sheila, Fary, David, Parrino, Patrick Eugene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320844/ https://www.ncbi.nlm.nih.gov/pubmed/35385586 http://dx.doi.org/10.1111/jocs.16452 |
Ejemplares similares
-
Ruptured hemorrhagic bulla in a patient with a HeartMate 3 treated with an Amplatzer device
por: daSilva-deAbreu, Adrian, et al.
Publicado: (2021) -
Left ventricular assist device exchange from HeartMate II to HeartMate 3 in an Asian patient—a case report and literature review
por: Chang, Hsiao-Huang, et al.
Publicado: (2023) -
Validation of non‐invasive ramp testing for HeartMate 3
por: Najjar, Emil, et al.
Publicado: (2020) -
Electrostatic Discharge Causing Pump Shutdown in HeartMate 3
por: Najjar, Emil, et al.
Publicado: (2021) -
Intraoperative pump thrombosis (PT) in HeartMate (HM) III
por: Karuppiah, Sathappan, et al.
Publicado: (2022)